Roche news from FiercePharma
NewsDrugmakers resist U.K. price goals
Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph Read more...
Drugmakers fighting for best U.K. deal
As the U.K. nears a long-term drug-pricing deal with pharma firms, drugmakers are grousing about the fact that the government decided to renegotiate at all. You'll recall that late last year, the Read more...
SPOTLIGHT: NICE rejects Roche drug as too costly
Roche's lung cancer med Tarceva got the goodbye gong from the U.K.'s National Institute for Clinical Excellence, which ruled that the drug wasn't a cost-effective option for treating non-small cell Read more...
Roche, Cipla trade jabs on Tarceva
We turn to India for updates on another cancer-drug battle, this one between Roche's brand-name Tarceva and Cipla's copycat version, Erlocip. A Roche distributor tattled to India's Drug Controller Read more...
Pfizer, Roche suffer as big drugs falter
Today's earnings roundup is a snapshot of pharma's challenges--generic Read more...
Falling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
FDA probes Roche, Novartis meds
The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. The Read more...
Roche appeals Mircera injunction
Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...
What did Vasella see in Alcon?
Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...
SPOTLIGHT: Novartis: No more deals, no Roche sale
Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for Read more...
| Press ReleasesPRESS RELEASE: Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Read more... PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more... PRESS RELEASE: Roche Confirms Commencement of Due Diligence with Ventana Roche Confirms Commencement of Due Diligence with Ventana Roche confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it Read more... PRESS RELEASE: Ventana Enters into Confidentiality Agreement with Roche Ventana Enters into Confidentiality Agreement with Roche TUCSON, Ariz. -- Nov. 13, 2007--Ventana Medical Systems, the global leader in tissue-based cancer diagnostics, today announced it has entered Read more... PRESS RELEASE: Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Read more... |
Get more Roche coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight